Toni Choueiri, MD, Dana-Farber Cancer Institute, joins the show to guest host a discussion with Rana McKay, MD, UC San Diego, and Alicia Morgans, MD, MPH, Northwestern University, on the practice-changing abstracts presented at the 2020 ASCO-GU virtual meeting. The trio weigh the importance and real-world implications of the ACIS study for mCRPC, EV-301 for advanced or metastatic urothelial carcinoma as well as CheckMate 274 for muscle-invasive disease, CLEAR for first-line treatment of advanced RCC, and so much more.
No related resources available.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
